AtaiBeckley Inc. (ATAI)
Eli Lilly to Boost Neuroscience Pipeline With AtaiBeckley Buyout
LLY agrees to acquire AtaiBeckley for $2.8B upfront to expand its neuroscience pipeline with psychedelic therapies for mental health disorders.
AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics, says Jefferies
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC)'s acquisition by Eli Lilly for up to $3.8 billion reinforces growing interest from large pharmaceutical companies in psychedelic-based therapies, according to analysts at Jefferies, who believe that the deal reflects increasing momentum driven by advancing clinical data and an improving regulatory backdrop. The acquisition, previously announced by Lilly, values AtaiBeckley at $6.75 per share in cash, or about $2.8 billion in equity, plus a contingent value right of up to $2.50 per share, worth roughly $1 billion if certain milestones are achieved.
Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug
CNBC pharma reporter Angelica Peebles broke down the biggest psychedelics deal in Big Pharma history on July 16, 2026.
ATAI Stock Soars on Reports of Potential Acquisition by Eli Lilly
AtaiBeckley stock surges after a Bloomberg report said Eli Lilly is in talks for a potential acquisition of the company, as investors await details of the deal.
Lilly Buys Psychedelic Drugmaker AtaiBeckley for $3.8 Billion
Eli Lilly & Co. agreed to buy AtaiBeckley Inc. for as much as $3.8 billion, underscoring growing interest from large drugmakers in psychedelic medicine. Madison Muller has more on "Bloomberg Open Interest.
Eli Lilly to Buy AtaiBeckley for Initial $2.8 Billion
Eli Lilly has struck a deal to buy mental-health-focused AtaiBeckley for an initial $2.8 billion, continuing the drugmaker's recent buying spree.
Is AtaiBeckley Inc (ATAI) Stock Outpacing Its Medical Peers This Year?
Here is how AtaiBeckley Inc (ATAI) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
AtaiBeckley set to unlock value from positive depression therapy trial results, says Jefferies
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) could see increased investor attention as it approaches Phase IIb data for its oral DMT-based therapy VLS-01, according to Jefferies analysts, who highlighted the program's potential to add value to the company's psychedelic medicine pipeline. The analysts wrote that VLS-01's completed Phase IIb enrollment in treatment-resistant depression (TRD) sets up a fourth quarter 2026 topline data readout, which could serve as a potential de-risking event for the program.
AtaiBeckley Completes VLS-01 Dosing in Phase IIb Depression Study
ATAI completes dosing in the phase IIb Elumina study of VLS-01 for treatment-resistant depression, with top-line efficacy and safety data due in fourth-quarter 2026.
AtaiBeckley completes dosing in Phase 2b depression trial, expects topline data in Q4
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) said on Monday that it has completed dosing the final patient in its Phase 2b Elumina clinical trial evaluating investigational therapy VLS-01 for adults with treatment-resistant depression (TRD), with topline results expected in the fourth quarter of 2026. The randomized, double-blind, placebo-controlled trial enrolled 156 patients across multiple centers.
AtaiBeckley: BPL-003's Promising Potential On TRD Keeps Me Bullish
ATAI is now a more focused psychedelics biotech. Particularly, BPL-003 is their main bet on TRD's sizeable TAM. BPL-003 has aligned its research with the FDA's feedback and will proceed with a two-study Phase 3 trial. We'll see its topline readouts by early 2029. ATAI also has VLS-01, which gives it a nearer-term Q4 2026 TRD catalyst. EMP-01 adds some optionality in social anxiety disorders as well.
AtaiBeckley to join Russell 2000 and Russell 3000 indexes following annual reconstitution
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) announced on Thursday that it will be added to the Russell 2000 Index and the Russell 3000 Index, effective at the open of US markets on June 29, as part of the 2026 Russell indexes reconstitution. The clinical-stage biotechnology company said the inclusion broadens its exposure to institutional investors and index-tracking funds.
